Netahawl Eye Drops contain Netarsudil (0.2 mg), a Rho-kinase inhibitor ophthalmic solution designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. It provides a targeted approach for long-term ocular pressure management, helping prevent optic nerve damage and preserve vision.
Netarsudil works by increasing trabecular meshwork outflow and lowering episcleral venous pressure, offering a dual mechanism for superior IOP control. This makes Netahawl highly effective for patients who require advanced glaucoma management, including those not fully controlled by conventional therapies.
The formulation supports once-daily dosing, improving patient adherence and ensuring consistent therapeutic outcomes. Ophthalmologists often prefer Netarsudil for its efficiency, safety, and predictable IOP reduction in long-term care.
From a business perspective, Netahawl Eye Drops strengthen the anti-glaucoma ophthalmic portfolio, providing high-value prescriptions, repeat sales, and long-term revenue potential for PCD pharma franchise partners. Its clinical effectiveness and prescriber trust make it a profitable addition for distributors and stockists across India.